FIELD: medicine, pharmaceutics.
SUBSTANCE: oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or its salt, polyvinylpyrrolidone and an alkaline compound, solution 5 % wt/vl of which has pH 10 or more. The preferential alkaline compound is L-arginine of potassium carbonate or sodium hydroxide. The oral composition can be presented in the form of a solid form or in the form of a water solution.
EFFECT: oral composition under the invention exhibits the improved gastrointestinal absorption and keeps stable solubility even with gastrointestinal pH variations.
10 cl, 51 ex
